导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.14% | 3902/4773 |
| 近一周 | -1.47% | 2195/5465 |
| 近一月 | -7.62% | 4622/5421 |
| 近一季 | -17.33% | 4582/5231 |
| 近半年 | -20.65% | 4407/4920 |
| 近一年 | -6.81% | 3226/4394 |
| 近两年 | 33.12% | 2161/2954 |
| 近三年 | 5.09% | 1840/2253 |
| 成立以来 | 36.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.95% 626/4961 |
0.77% 3132/5312 |
- - |
- - |
| 2025 | 27.37% 1562/4813 |
-4.34% 3166/3635 |
0.06% 2769/4076 |
35.35% 994/4524 |
-1.68% 2990/4813 |
| 2024 | 2.56% 1969/3463 |
-2.06% 1312/2808 |
-7.32% 2068/3014 |
18.40% 1011/3129 |
-4.58% 2479/3463 |
| 2023 | -28.12% 2032/2656 |
-2.95% 2057/2280 |
-5.51% 1480/2385 |
-14.32% 2180/2515 |
-8.52% 2295/2655 |
| 2022 | -23.64% 1155/2207 |
-14.91% 1010/1919 |
14.12% 209/2016 |
-16.01% 1389/2113 |
-6.36% 1992/2208 |
| 2021 | 42.14% 24/1822 |
-4.97% 898/1255 |
27.93% 56/1330 |
17.01% 69/1466 |
-0.08% 1196/1822 |
| 2020 | 53.69% 148/1250 |
-5.91% 446/1028 |
14.59% 543/1067 |
15.15% 234/1164 |
23.79% 39/1184 |
| 2019 | 19.82% 673/1092 |
24.47% 512/739 |
-9.49% 660/788 |
-1.17% 635/850 |
7.61% 420/918 |
| 2018 | -36.07% 586/834 |
- - |
-17.06% 571/631 |
-10.19% 536/660 |
-9.22% 136/682 |
| 2017 | 0.47% 478/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发中证环保ETF联接C VS. 长安沪深300非周期A(740101) |